Cancer treatment pipeline expands across vaccines, targeted drugs, and precision tools

Promising oncology signals include improved outcomes with bezuclastinib plus sunitinib in KIT-mutant GIST and encouraging topline results for a personalized mRNA melanoma vaccine combined with pembrolizumab. Tumor-on-a-chip testing and other experimental therapies add momentum, but much of the evidence is preliminary, company-reported, or preclinical.